ALDXAldeyra Therapeutics, Inc.Signing up patients
A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma
Primary Vitreoretinal Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 20 (planned)
- Started
- Feb 2026
- Main results expected
- Dec 2026
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Proportion of clearance of lymphomatous vitreous cells compared across ICM and monthly ADX-2191 treatment groups after eight weeks of treatment
Measured over: Eight weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07402876 · record last updated 2026-02-11 · checked 2026-11-09 15:36 UTC